Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cosmo Pharmaceuticals N.V.    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations
Communiqués de presse de la société COSMO PHARMACEUTICALS N.V.
01/13Acacia Pharma enters into strategic in-licensing, investment and loan transac..
AQ
01/13Cosmo sub-licenses its ByFavo US rights to Acacia Pharma, takes an initial 14..
AQ
01/10Cosmo sub-licenses its ByFavo™ (Remimazolam) US rights to Acacia Pharma..
TE
2019RedHill Biopharma Initiates U.S. Promotion of Aemcolo for Travelers' Diarrhea
AQ
2019COSMO PHARMACEUTICALS N : announces worldwide exclusive Distribution Agreement f..
AQ
2019Cosmo Pharmaceuticals announces worldwide exclusive Distribution Agreement fo..
TE
2019COSMO PHARMACEUTICALS N : appoints New CSO; as current CSO retires
PU
2019Cosmo appoints New CSO as current CSO retires
TE
2019Cosmo's Partner RedHill announces approval of Talicia for the treatment of H...
AQ
2019Cosmo's Partner RedHill gibt die Zulassung von Talicia® für die Behandlung vo..
TE
2019Cosmo's Partner RedHill announces approval of Talicia® for the treatment of H..
TE
2019Cosmo licenses Aemcolo for the USA to RedHill Biopharma and takes a 19.56% st..
AQ
2019RedHill Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals a..
AQ
2019Cosmo licenses Aemcolo™ for the USA to RedHill Biopharma and takes a 19..
TE
2019Cosmo Half-Year Report 2019
TE
2019Cosmo Pharmaceuticals Posts GI Genius Video Demonstration at Image 2019 Confe..
TE
2019COSMO PHARMACEUTICALS : announces Canadian Agency approval of Eleview for endosc..
AQ
2019Cosmo Pharmaceuticals announces Canadian Agency approval of Eleview® for endo..
TE
2019COSMO PHARMACEUTICALS : announces Publication of Review of Aemcolo as Treatment ..
AQ
2019Cosmo Pharmaceuticals announces Publication of Review of Aemcolo™ as Tr..
TE
2019COSMO PHARMACEUTICALS : N.V. - FDA accepts filing of NDA for Remimazolam
AQ
2019FDA accepts filing of NDA for Remimazolam
TE
2019COSMO PHARMACEUTICALS' : Shareholders approve all Agenda Items at Annual General..
AQ
2019Cosmo Pharmaceuticals' Shareholders approve all Agenda Items at Annual Genera..
TE
2019COSMO PHARMACEUTICALS : New exclusive Distribution Agreement for Eleview with Me..
AQ
2019COSMO PHARMACEUTICALS : FDA Allowance of IND application for CB-03-10
AQ
2019COSMO PHARMACEUTICALS : New exclusive Distribution Agreement for Eleview with Me..
TE
2019COSMO PHARMACEUTICALS : FDA Allowance of IND application for CB-03-10
TE
2019Cosmo Pharmaceuticals announces agenda of the R&D Day 2019
TE
2019Cosmo Pharmaceuticals announces revolutionary Artificial Intelligence device ..
TE
2019Cosmo Pharmaceuticals Announces Submission of Remimazolam NDA to FDA
TE
2019Cosmo Full-Year Report 2018
AQ
2019Cosmo Full-Year Report 2018
TE
2019COSMO PHARMACEUTICALS : announces new R&D Day on May 8, 2019 in Zurich to inform..
AQ
2019Cosmo Pharmaceuticals announces new R&D Day on May 8, 2019 in Zurich to infor..
TE
2019Cosmo Pharmaceuticals announces denial of Methylene Blue MMX appeal and begin..
TE
2019Cosmo Pharmaceuticals Files Marketing Authorization Application for Methylene..
TE
2018COSMO PHARMACEUTICALS METHYLENE BLUE : new appeal filing – Next steps
TE
2018Cosmo Issues EUR 175 million Convertible Bond
TE
2018Cosmo announces its licensee Dr. Falk Pharma received approval in the Europea..
TE
2018Cosmo Pharmaceuticals N.V. Pressemitteilung
TE
2018Cosmo Pharmaceuticals N.V. Media Release
TE
2018COSMO PHARMACEUTICALS : Media Release November 28, 2018
PU
2018FDA Approves AEMCOLO™ (Rifamycin), the First Antibiotic Approved for th..
TE
2018COSMO PHARMACEUTICALS METHYLENE BLUE : Initial appeal outcome – Next steps
PU
2018COSMO PHARMACEUTICALS METHYLENE BLUE : Type A Meeting outcome – Next steps
TE
2018Cosmo Half-Year Report 2018
TE
2018Cosmo Pharmaceuticals Announces Cassiopea's Very Positive Top-Line Phase 3 Re..
TE
2018Cosmo Pharmaceuticals updates on Uceris®
TE
2018COSMO PHARMACEUTICALS METHYLENE BLUE : Type A Meeting Request filed to FDA
TE
2018Cosmo Pharmaceuticals' Shareholders approve all Agenda Items at Annual Genera..
TE
2018Cosmo Pharmaceuticals Receives Complete Response Letter from the FDA on Methy..
TE
2018COSMO PHARMACEUTICALS : Receives Complete Response Letter from the FDA on Methyl..
PU
2018FDA accepts new drug application submission for Cosmo Pharmaceutical's Rifamy..
TE
2018Cosmo Pharmaceuticals provides Methylene Blue MMX regulatory update
TE
2018Cosmo Pharmaceuticals announces unfavourable award of Arbitral Tribunal in re..
TE
2018Cosmo Full-Year Report 2017
TE
2018Cosmo Pharmaceuticals signs with EA Pharma Co., Ltd. Exclusive License Agreem..
TE
2018Cosmo announces submission to FDA of New Drug Application for Rifamycin SV MM..
TE
2018Cosmo Pharmaceuticals and FUJIFILM Expand Distribution Agreement for Eleview
TE
2018Cosmo Pharmaceuticals and Pharmascience establish License and Supply Agreemen..
TE
2017Cosmo Pharmaceuticals Announces First Patient Randomized In Its Proof Of Conc..
TE
2017Update on lawsuit against patent infringement on Uceris®
TE
2017Update on commercialization of Rifamycin SV MMX®
TE
2017Update zur Kommerzialisierung von Rifamycin SV MMX®
TE
2017COSMO PHARMACEUTICALS : FDA Grants Cosmo Pharmaceuticals Both QIDP and Fast Trac..
BU
2017Cosmo Pharmaceuticals and Fujifilm Establish Distribution Agreement for Elevi..
TE
2017FDA Grants Cosmo Pharmaceuticals both QIDP and Fast Track Designations for Ae..
TE
2017COSMO PHARMACEUTICALS : FDA Grants Cosmo Pharmaceuticals both QIDP and Fast Trac..
PU
2017FDA accepts new drug application submission for Cosmo Pharmaceutical's Methyl..
TE
2017Cosmo Pharmaceuticals and Olympus America Inc. Establish Co-Promotion Agreeme..
TE
2017Cosmo Half-Year Report 2017
TE
2017Cosmo announces European approval of Qolotag® for sigmoidoscopies in IBD pati..
TE
2017COSMO PHARMACEUTICALS : announces European approval of Qolotag® for sigmoidoscop..
PU
2017Cosmo announces submission to FDA of new drug application for LuMeBlue®
TE
1  2Next
Upcoming event on COSMO PHARMACEUTICALS N.V.